Remove 2014 Remove Gordon Remove Innovation Remove Management
article thumbnail

We Need More Transparency on the Cost of Specialty Drugs

Harvard Business Review

In a July 2014 JAMA article , Troyen Brennan and William Shrank, respectively the chief medical and scientific officers at CVS Caremark, a major pharmacy benefit manager (PBM), estimated that with as many as 3 million eligible HCV patients in the U.S., In one analysis , Gordon D. Health Innovation'

Cost 8
article thumbnail

We Need More Transparency on the Cost of Specialty Drugs

Harvard Business Review

In a July 2014 JAMA article , Troyen Brennan and William Shrank, respectively the chief medical and scientific officers at CVS Caremark, a major pharmacy benefit manager (PBM), estimated that with as many as 3 million eligible HCV patients in the U.S., In one analysis , Gordon D. Health Innovation'

Cost 8
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Applying Deming Principles at Small and Medium-sized Enterprises

Deming Institute

In 2014, I applied for and received a grant from The W. In 2014, as in previous years, the dominant reason for discontinuation of a venture in Latin America, Africa, Europe, Asia and Oceania was that the business was not profitable, as per the Global Entrepreneurship Monitor 2014 Global report.

Deming 28
article thumbnail

The H-1B Visa Debate, Explained

Harvard Business Review

According to an analysis by Ronil Hira, a professor of public policy at Howard University, in 2014 nearly one-third of new H-1B visas went to 13 of these so-called “outsourcers.” on H-1B visas, boost the economy by increasing innovation, productivity, and sometimes even employment. “But more engineers is a good thing.